Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
← catalyst calendarNCT07520006 · readout ≤ 2,477 d
Sponsored by Nurix Therapeutics, Inc. (industry) · NRIX — their whole pipeline →.
Phase
Phase 1/2
Status
Not yet recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
150estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | May 2026 | estimated | When the study began enrolling |
| Primary completion | May 2033 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2033 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- B-cell Lymphoma
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
Interventions
- Drug: NX-5948 — also filed as bexobrutideg
- Drug: venetoclax
- Drug: rituximab
- Drug: obinutuzumab
Primary outcome
what the primary-completion date above is the date OFNumber of participants with treatment-emergent adverse events
measured Up to approximately 7 years
Permalink · NRIX's whole pipeline · Catalyst calendar · Every registered study · What changed